Use of curcumin in the treatment of Ulcerative Colitis
DOI:
https://doi.org/10.33448/rsd-v11i5.28480Keywords:
Colitis Ulcerative; Curcumin; Curcuma; Health teaching.Abstract
The present study is a literary review on the use of curcumin in the treatment of ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD), which has as clinical manifestations diarrhea and hematochezia. We sought to gather data from clinical trials, experimental studies and literary reviews, on turmeric therapy in the treatment of UC compared to conventional treatment have seen the increased incidence of IBD and its high drug cost. Curcumin, one of the active ingredients of this herbal medicine, has an anti-inflammatory effect previously observed in other conditions, and demonstrated efficacy in clinical remission of UC in animal models and as adjunct therapy to standard treatment in humans, reducing its chances of recurrence and the risk of developing dysplasia and neoplasms, as well as endoscopic improvement and intestinal motility, which added to the absence of important adverse effects is unique for improving the quality of life of patients with UC who make their use. Thus, it is important to recognize turmeric as an alternative therapy and encourage further studies addressing its use in the treatment of UC, since it is a widely available herbal medicine in our environment and has great medicinal potential.
References
Adams, S. M., & Bornemann, P. H. (2013). Ulcerative colitis. American family physician, 87(10), 699–705. PMID: 23939448
Aldini, R., Budriesi, R., Roda, G., Micucci, M., Ioan, P., D'Errico-Grigioni, A., Sartini, A., Guidetti, E., Marocchi, M., Cevenini, M., Rosini, F., Montagnani, M., Chiarini, A., & Mazzella, G. (2012). Curcuma longa extract exerts a myorelaxant effect on the ileum and colon in a mouse experimental colitis model, independent of the anti-inflammatory effect. PloS one, 7(9), 446-450. doi: 10.1371%2Fjournal.pone.0044650
Araújo, O. R. P. (2019). Avaliação da capacidade antioxidante e anti-inflamatória da Curcuma longa, em diferentes tecidos de camundongos saudáveis e/ou com colite ulcerativa moderada induzida por sulfato de sódio dextrana. Universidade Federal de Alagoas, Maceió, Brasil.
Baliga, M. S., Joseph, N., Venkataranganna, M. V., Saxena, A., Ponemone, V., & Fayad, R. (2012). Curcumin, an active component of turmeric in the prevention and treatment of ulcerative colitis: preclinical and clinical observations. Food & function, 3(11), 1109–1117. doi: 10.1039/c2fo30097d
Beloqui, A., Memvanga, P. B., Coco, R., Reimondez-Troitiño, S., Alhouayek, M., Muccioli, G. G., Alonso, M. J., Csaba, N., de la Fuente, M., & Préat, V. (2016). A comparative study of curcumin-loaded lipid-based nanocarriers in the treatment of inflammatory bowel disease. Colloids and surfaces. B, Biointerfaces, 143, 327–335. doi: 10.1016/j.colsurfb.2016.03.038
Biblioteca Prof. Paulo de Carvalho Mattos (2015). Tipos de Revisão de Literatura. Faculdade de Ciências Agronômicas UNESP, Botucatu. https://www.fca.unesp.br/Home/Biblioteca/tipos-de-evisao-de-literatura.pdf
Camacho-Barquero, L., Villegas, I., Sánchez-Calvo, J. M., Talero, E., Sánchez-Fidalgo, S., Motilva, V., & Alarcón de la Lastra, C. (2007). Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. International immunopharmacology, 7(3), 333–342. doi: 10.1016/j.intimp.2006.11.006
Coelho, M. R., Romi, M. D., Ferreira, D., Zaltman, C., & Soares-Mota, M. (2020). The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systematic Review of Randomized Controlled Clinical Trials. Nutrients, 12(8), 2296. doi: 10.3390/nu12082296
Cordeiro, A. M., Oliveira, G. M., Rentería, J. M. & Guimarães, C. A. (2007). Revisão sistemática: uma revisão narrativa. Revista do Colégio Brasileiro de Cirurgiões, 34(6), 428-431. doi: 10.1590/S0100-69912007000600012
Correia A. M. R. & Mesquita A (2014). Mestrados e Doutoramentos. Porto: Vida Economica Editorial, 2ª edição, 217-218.
Garg, S.K., Ahuja, V., Sankar, M. J., Kumar, A., & Moss, A. C. (2012). Curcumin for maintenance of remission in ulcerative colitis. The Cochrane database of systematic reviews, 10, CD008424. doi: 10.1002/14651858.CD008424.pub2
Goulart, R. A., Barbalho, S. M., Lima, V. M., Souza, G. A., Matias, J. N., Araújo, A. C., Rubira, C. J., Buchaim, R. L., Buchaim, D. V., Carvalho, A., & Guiguer, É. L. (2021). Effects of the Use of Curcumin on Ulcerative Colitis and Crohn's Disease: A Systematic Review. Journal of medicinal food, 24(7), 675–685. doi: 10.1089/jmf.2020.0129
Grammatikopoulou, M. G., Gkiouras, K., Theodoridis, X., Asteriou, E., Forbes, A., & Bogdanos, D. P. (2018). Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients, 10(11), 1737. doi: 10.3390/nu10111737
Gupta, S. C., Tyagi, A. K., Deshmukh-Taskar, P., Hinojosa, M., Prasad, S., & Aggarwal, B. B. (2014). Downregulation of tumor necrosis factor and other proinflammatory biomarkers by polyphenols. Archives of biochemistry and biophysics, 559, 91–99. doi: 10.1016/j.abb.2014.06.006
Kadri, C. J., Pereira, J. A., Campos, F. G., Ortega, M. M., Bragion, C. B., & Martinez, C. A. (2017). Anti-inflammatory effects of enemas containing an oily extract of curcumin in an experimental model of diversion colitis. Histology and histopathology, 32(2), 161–169. doi: 10.14670/HH-11-783
Kampa, K. C., Morsoletto, D. B. G., Loures, M. R., Pissaia Junior, A., Nones, R. B., & Ivantes, C. A. P. (2017). Importance of measuring levels of infliximab in patients treating inflammatory bowel disease in a Brazilian cohort. Arquivos de Gastroenterologia. 54(4), 333-337. doi: 10.1590/S0004-2803.201700000-41.
Klotz, C.; Barret, M.; Dhooge, M.; Oudjit, A.; Chaussade, S.; Coriat, R.; & Abitbol, V. (2015). Rectocolite hémorragique: conduite diagnostique et prise en charge thérapeutique. La Presse Médicale, 44(2), 144-149. doi : 10.1016/j.lpm.2014.06.025
Kocaadam, B., & Şanlier, N. (2017). Curcumin, an active component of turmeric (Curcuma longa), and its effects on health. Critical reviews in food science and nutrition, 57(13), 2889–2895. doi: 10.1080/10408398.2015.1077195
Lang, A., Salomon, N., Wu, J. C., Kopylov, U., Lahat, A., Har-Noy, O., Ching, J. Y., Cheong, P. K., Avidan, B., Gamus, D., Kaimakliotis, I., Eliakim, R., Ng, S. C., & Ben-Horin, S. (2015). Curcumin in Combination with Mesalamine Induces Remission in Patients with Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association, 13(8), 1444–9. doi: 10.1016/j.cgh.2015.02.019
Lima, A. M.; Nascimento, C. H. C.; Santos, C. H. M.; Dourado, D. M.; Siqueira, G. E. C.; Rigo, G. M.; Bernardi, L. U.; Leonel, P. O. S.; Matias, R.; Ferreira, V. C.; & Souza, V. C. P. (2019). Eficácia da Curcuma Longa no Tratamento da Colite de Desuso em Ratos. Arquivos Brasileiros de Cirurgia Digestiva (ABCD), 32(3), e1456. doi: 10.1590/0102-672020190001e1456
Malik T. A. (2015). Inflammatory Bowel Disease: Historical Perspective, Epidemiology, and Risk Factors. The Surgical clinics of North America, 95(6), 1105–1122. doi: 10.1016/j.suc.2015.07.006
Moretes, D. N. & Geron, V. L. M. G. (2019). Os benefícios medicinais da curcuma longa l. (açafrão da terra). Revista Científica Da Faculdade De Educação E Meio Ambiente, 10(1), 106–114. doi: 10.31072/rcf.v10iedesp.767
Ordás, I., Eckmann, L., Talamini, M., Baumgart, D. C., & Sandborn, W. J. (2012). Ulcerative colitis. Lancet (London, England), 380(9853), 1606–1619. doi: 10.1016/S0140-6736(12)60150-0
Prasad, S., Tyagi, A. K., & Aggarwal, B. B. (2014). Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer research and treatment, 46(1), 2–18. doi: 10.4143/crt.2014.46.1.2
Sadeghi, N., Mansoori, A., Shayesteh, A., & Hashemi, S. J. (2020). The effect of curcumin supplementation on clinical outcomes and inflammatory markers in patients with ulcerative colitis. Phytotherapy research: PTR, 34(5), 1123–1133. doi: 10.1002/ptr.6581
Sehgal, P., Colombel, J. F., Aboubakr, A., & Narula, N. (2018). Systematic review: safety of mesalazine in ulcerative colitis. Alimentary pharmacology & therapeutics, 47(12), 1597–1609. doi: 10.1111/apt.14688
Silverberg, M. S., Satsangi, J., Ahmad, T., Arnott, I. D., Bernstein, C. N., Brant, S. R., Caprilli, R., Colombel, J. F., Gasche, C., Geboes, K., Jewell, D. P., Karban, A., Loftus, E. V., Jr, Peña, A. S., Riddell, R. H., Sachar, D. B., Schreiber, S., Steinhart, A. H., Targan, S. R., Vermeire, S., & Warren, B. F. (2005). Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 19 Suppl A, 5–36. doi: 10.1155/2005/269076
Simadibrata, M., Halimkesuma, C. C., & Suwita, B. M. (2017). Efficacy of Curcumin as Adjuvant Therapy to Induce or Maintain Remission in Ulcerative Colitis Patients: an Evidence-based Clinical Review. Acta medica Indonesiana, 49(4), 363–368. Disponível em: http://www.actamedindones.org/index.php/ijim/article/view/520/pdf
Sreedhar, R., Arumugam, S., Thandavarayan, R. A., Karuppagounder, V., & Watanabe, K. (2016). Curcumin as a therapeutic agent in the chemoprevention of inflammatory bowel disease. Drug discovery today, 21(5), 843–849. doi: 10.1016/j.drudis.2016.03.007
Sugimoto, K., Ikeya, K., Bamba, S., Andoh, A., Yamasaki, H., Mitsuyama, K., Nasuno, M., Tanaka, H., Matsuura, A., Kato, M., Ishida, N., Tamura, S., Takano, R., Tani, S., Osawa, S., Nishihira, J., & Hanai, H. (2020). Highly Bioavailable Curcumin Derivative Ameliorates Crohn's Disease Symptoms: A Randomized, Double-Blind, Multicenter Study. Journal of Crohn's & colitis, 14(12), 1693–1701. doi: 10.1093/ecco-jcc/jjaa097
Suskind, D. L., Wahbeh, G., Burpee, T., Cohen, M., Christie, D., & Weber, W. (2013). Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study. Journal of pediatric gastroenterology and nutrition, 56(3), 277–279. doi: 10.1097/MPG.0b013e318276977d
Teixeira, F. V., & Saad-Hosne, R. (2015). Management of ulcerative colitis: a clinical update. Journal of Coloproctology (Rio de Janeiro), 35(4), 230-237. doi: 10.1016/j.jcol.2015.08.006
Teixeira, F. V.; Saad-Hosne, R.; Carpi, M. R.; Teixeira, A. C. A.; & Júnior, P. T. (2008). Infliximabe no tratamento inicial da retocolite ulcerativa moderada e grave. Terapia top down: relato preliminar. Revista Brasileira de Coloproctologia, 28(3), 289-293. doi: 10.1590/S0101-98802008000300003
Toden, S., Theiss, A. L., Wang, X., & Goel, A. (2017). Essential turmeric oils enhance anti-inflammatory efficacy of curcumin in dextran sulfate sodium-induced colitis. Scientific reports, 7(1), 814. doi: 10.1038/s41598-017-00812-6
Ung, V. Y., Foshaug, R. R., MacFarlane, S. M., Churchill, T. A., Doyle, J. S., Sydora, B. C., & Fedorak, R. N. (2010). Oral administration of curcumin emulsified in carboxymethyl cellulose has a potent anti-inflammatory effect in the IL-10 gene-deficient mouse model of IBD. Digestive diseases and sciences, 55(5), 1272–1277. doi: 10.1007/s10620-009-0843-z
Ungaro, R., Mehandru, S., Allen, P. B., Peyrin-Biroulet, L., & Colombel, J. F. (2017). Ulcerative colitis. Lancet (London, England), 389(10080), 1756–1770. doi: 10.1016/S0140-6736(16)32126-2
Wehkamp, J., & Stange, E. F. (2018). Recent advances and emerging therapies in the non-surgical management of ulcerative colitis. F1000Research, (7), 1207. doi :10.12688/f1000research.15159.1
Yamamoto-Furusho, J. K., Gutiérrez-Grobe, Y., López-Gómez, J. G., Bosques-Padilla, F., Rocha-Ramírez, J. L., & Grupo del Consenso Mexicano de Colitis Ulcerosa Crónica Idiopática (2018). The Mexican consensus on the diagnosis and treatment of ulcerative colitis. Consenso mexicano para el diagnóstico y tratamiento de la colitis ulcerosa crónica idiopática. Revista de gastroenterologia de Mexico (English), 83(2), 144–167. doi: 10.1016/j.rgmx.2017.08.006
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Carlos Henrique Marques Santos; Ana Luísa Marques Torresilha; Gabriela Cruz Momm; Giovanna Larsen Yamaki; Matheus Santana de Souza; Newton Signorini Castilho; Stéfany Teles Vieira
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
